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Abstract 
Colorectal cancer (CRC) is the second leading cause of cancer deaths in Canada. The 
high mortality rate for CRC patients demonstrate the urgent need for a convenient, 
accurate and cost-effective screening test, which could triage patients for more intensive 
procedures such as colonoscopy. Current CRC screening tests are limited by their 
efficacy, invasiveness, and poor acceptability by the patients. N-myristoylation refers to 
the covalent attachment of the 14-carbon fatty acid myristoyl group to the N-terminal 
glycine residue of a target protein, which ensures its proper functioning and intracellular 
trafficking. This reaction is common amongst signalling proteins and is often integral to 
their activity. Myristoylation is catalyzed by N-myristoyltransferase which transfers the 
myristoyl moiety from myristoyl-coenzyme A to the N-terminal glycine residue.  
The foremost aim of my study was to optimize and quantify NMT1 and METAP2 gene 
expression by using quantitative Polymerase Chain Reaction (qPCR). Due to its capacity 
to generate both qualitative and quantitative results, qPCR is considered a quick and 
accurate technique to begin with. NMT1 and METAP2 oncogenes overexpressed in 
colorectal cancer cells are directly associated with aggressive clinical behaviour. The 
NMT1 and METAP2 oncogenes and their respective protein products (NMT1 and 
METAP2) have been utilized for disease diagnosis and as predictive markers for 
treatment. To support accurate quantification and analysis in this study, I have optimized 
and standardized qPCR analysis to analyze colorectal cancer samples, obtaining 
significant and clinically useful results. We recently demonstrated that NMT1 is 
expressed in the peripheral blood mononuclear cells (PBMC) and T cells of colorectal 
cancer patients. The aims of this study are to quantify NMT1 and METAP2 expression in 
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individuals undergoing colonoscopy and determine whether NMT1 and METAP2 gene 
expression could serve as a screening marker for CRC.  
Chapter two: From chapter 1, it was determined that NMT1 and METAP2 expressions in 
peripheral blood and PBMC are potential biomarkers for CRC screening. These 
biomarkers are overexpressed in individuals with polyps and CRC. To understand the 
mechanism and the functional relevance of NMT1 and METAP2 overexpression in 
PBMC, Nmt1 was knocked out in mouse embryonic stem cells and its effect was 
investigated on metabolic pathway. The generation of homozygous (Nmt1-/-) deficient 
embryonic stem cells was confirmed by qPCR and Western analysis. The depletion of 
NMT1 leads to enhanced phosphorylation of key proteins within the PI3K/Akt signalling 
pathway that are normally stimulated by insulin and inhibited by rapamycin. The Nmt1-
deficiency resulted in the over activation of the PI3K/Akt signalling pathway and Igf1r 
gene expression, thus, NMT1 likely has a vital role in regulating metabolic disorders.  
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CHAPTER 1: N-myristoyltransferase 1 and Methionine Aminopeptidase 2 are novel 
biomarkers for early detection of colorectal adenomatous polyps and cancers 
 
Colorectal Cancer 
Colorectal cancer (CRC) is a common malignant disease and a major cause of 
mortality worldwide. Currently, it is the second most commonly diagnosed cancer in 
Canada, affecting approximately 25,000 Canadians [1]. CRC accounts for 13% of the 
annual incidence of cancer in Canada for men and 11% for women [1]. According to 
American Cancer Society, 1 in 22 men and 1 in 24 women are at a risk of developing the 
disease. The estimated number of CRC cases in United States for 2017 were reported to 
be as high as 95, 270 new cases of colon cancer and 39, 220 new cases of rectal cancer 
[2]. Compared to other cancers, CRC is a highly treatable cancer if it is detected early and 
it is up to 90% preventable with timely and thorough CRC screening. Unfortunately, as it 
stands today, nearly half of those diagnosed find out too late [2]. There are two types of 
colon polyps: non-neoplastic polyps and neoplastic polyps [3]. The non-neoplastic polyps 
are hyperplastic or inflammatory (non-adenomatous) but are non-precancerous. However, 
neoplastic polyps (adenomatous polyps or adenomas), are benign neoplasms that can 
progress to form cancer and are precancerous in nature (Figure 1) [3]. Adenomatous 
polyps display some dysplasia, which can be graded into mild, moderate, and severe 
based on histology. Neoplastic polyps are histologically divided into 3 sub-groups: 
tubular adenomas, villous adenoma and mixed. Patients with tubular adenomas are at a 
3% risk of malignant tumor formation; while villous adenomas have 15% or higher risk 
of malignant formation [4, 5]. Due to their malignant nature, these polyps should be 
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identified and removed at the early stage to avoid the development of CRC. CRC begins 
as adenomatous polyps which is benign growth in the lining of the colon. Over the years, 
these adenomatous polyps grow larger and can differentiate, thereby increasing the risk 
of cells in the polyps becoming cancerous. Therefore, early detection of adenomatous 
polyps is an important step in preventing progression of CRC. It is important to identify 
and remove these polyps as soon as possible. Since CRC develops slowly from 
precancerous lesions, early detection and prompt removal of adenoma can decrease the 
incidence and mortality rate. Once polyps are detected, especially adenomatous polyps, 
an increased risk for colorectal carcinoma must be anticipated and appropriate 
surveillance becomes mandatory even after polypectomy. If the adenomatous polyps are 
not treated or removed they can develop into cancers, a process that takes at least 10 
years [6]. Early detection is the key to survival, however the surgical resection of the 
growth, often in combination with chemotherapy, significantly increases life expectancy. 
Currently available CRC screening tests such as fecal occult blood testing (FOBT), 
sigmoidoscopy, and colonoscopy have several limitations including: limited efficacy, the 
invasive nature of the test, and poor patient compliance [7]. 
 
Figure 1. Photographs showing normal, non-adenomatous polyp (NAP), adenomatous 
polyp (AP), and CRC colon. 
 
Normal	Colon	
Non-adenomatous	
polyp	 Adenomatous	polyp	 Colorectal	Cancer	
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N-myristoyltransferase (NMT) and Myristoylation 
Acylation of proteins by long chain fatty acids promotes binding of proteins to the 
inner leaflet of the plasma membrane and regulates their intracellular trafficking [8]. N-
myristoylation is an irreversible modification and co-translational lipid modification that 
involves the covalent attachment of a 14-carbon saturated myristoyl group to the N-
terminal glycine residue of a target protein. The myristoyl transfer is catalyzed by N-
myristoyltransferase (NMT) (Figure 2), and is known to occur in viruses, fungi, plants 
and in mammals, including mice, rats and humans. [9-13]. A myriad of proteins involved 
in a variety of signaling cascades and cellular differentiation are myristoylated [10, 11]. 
These include the catalytic subunit of cAMP-dependent protein kinase [14], the β-subunit 
of calcineurin [15], the α-subunit of several G-proteins [16], non-receptor tyrosine 
kinases such as Lck of T cells and the cellular and transforming forms of pp60src [17]. 
The eukaryotic NMT is a member of the GCN5-related N-acetyltransferase (GNAT) 
superfamily of proteins [9-11]. 
 
NMT and METAP2 
Lipid modification of proteins has received great attention recently as a target for 
therapeutic interventions to cancer [18]. Myristoylated proteins are involved in a variety 
of signal transductions, cellular proliferation, and oncogenesis [18]. Myristoylation is an 
integral part of apoptosis or programmed cell death [18]. In the PI3K/Akt/mTOR 
pathway, c-Src is frequently observed to be activated or over-expressed in a number of 
human cancers; especially those of colon and breast. Activation of c-Src and its 
subsequent oncogenic growth signaling requires myristoylation. In 1995, it was first 
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discovered that there was an increase in NMT enzyme activity in rat colonic cancer tissue 
compared to adjacent normal-appearing cells. To confirm that this phenomenon was not 
specific to the rat model, a small sample of human colonic adenocarcinomas tissue were 
measured to have hyperactivity of NMT [19]. In mammalian systems, NMT activity has 
been shown to increase in colorectal tumors, leading to the proposal that NMT enzyme 
could serve as a target for anticancer therapies [20] and the possibility of NMT having a 
vital role in human tumor progression. After 2 years, the same group correlated NMT 
Enzyme activity to NMT protein expression by using Western blot analysis. The results 
showed that all the human colonic tumor samples had high NMT protein expression.  
 
A newly synthesized protein will always have a methionine group at the N-
terminal. Methionine aminopeptidase (MetAP2) cleaves the Methionine residue and 
removes it. The end product is an N-terminus glycine residue protein. An N-terminus 
glycine residue protein is the only protein that can be myristoylated. Thus, MetAP2 is an 
upstream event and it is an important part of myristoylation reaction. In order for NMT to 
catalyze myristoylation at the N-terminal glycine of a target protein, the removal of N-
terminal methionine is required, as it is essential for further amino-terminal modifications 
and the maturation of many proteins. The methionine aminopeptidases (MetAPs) 
represent a unique class of proteases which remove the initiation methionine residue from 
newly synthesized polypeptide chains [21]. MetAPs catalyze N-terminal methionine 
excision (NME) - an essential pathway of co-translational protein maturation (Figure 
2) [22]. In some instances, the action of MetAP is required for biological activity, proper 
subcellular localization, and eventual degradation. This enzyme is present in both 
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eukaryotes and prokaryotes [22].  In yeast and humans, two proteins are known to 
possess MetAP activity: MetAP1 and MetAP2. MetAP2 has attracted much more 
attention than MetAP1 due to its discovery as a target molecule of the anti-angiogenic 
compounds fumagillin and ovalicin. In 2006, reports from Western blot analysis shows a 
higher expression of MetAP2 in all cases of cancerous tissues compared with normal 
tissues. In addition, immunohistochemistry analysis revealed that all cases of colorectal 
adenocarcinoma show strong cytoplasmic positivity for MetAP2 with increased intensity 
in the invasive component [23]. In summary, both NMT and MetAP2 were over-
expressed in the colonic tumor. In 2007, Dr. Shrivastav’s group investigated whether 
those molecular signatures can be found in peripheral blood, as blood is easier to collect 
and it is an alternative to tissue samples. They found an over-expression of NMT1 in 
peripheral blood smears of rats with cancer relative to healthy rats [24]. In addition, they 
collected blood samples from patients with cancer and they found an over-expression of 
NMT1 in peripheral blood smears in cancer patients compared to healthy individuals 
[24]. Overall, there was a high expression of NMT in both colonic tumors and peripheral 
blood samples, but there have only been reports on the high expression of MetAP2 in the 
colonic tumor. 
 
Since the myristoylation reaction is catalyzed by NMT, after removal of 
methionine by MetAP2, I investigated the correlation between MetAP2 and NMT1. It 
appears that higher expression of MetAP2 is required for the over-expression of NMT1 in 
colon carcinogenesis. The elevated NMT activity during colonic carcinogenesis may be 
due to the higher demand for myristoylation of various proteins/oncoproteins which are 
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overexpressed and activated during tumorigenesis. A direct relationship between elevated 
NMT expression and activity in colon cancer progression has been reported [18]. NMT1 
and MetAP2 can be a putative therapeutic drug target for CRC if the patient is diagnosed 
at an early stage. This study focused on the role of NMT1 and METAP2 gene expression 
in healthy, noncancerous adenomatous polyps, and CRC patients. These enzymes can be 
modulated by growth factors [25] and may be of importance in cancer development and 
therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Myristoylation reaction catalyzed by N-myristoyltransferase (NMT). The 
myristoyl functional group is added to the N-terminal glycine residue co-translationally 
following the removal of the N-terminal methionine residue by methionine 
aminopeptidase (MetAP) and the synthesis of myristoyl-CoA by acyl-CoA synthetase. 
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Whole Blood 
The peripheral blood expression profile represents a promising tool to discover 
biomarkers associated with physiological or pathological events. Circulating blood is 
easily accessible and can represent an alternative to tissue sampling for the purpose of 
finding molecular signatures. Here in we describe measuring gene expression from 
patient whole blood samples. This method consists in the combination of PAXgene™ 
tubes containing an mRNA stabilizer for blood collection, and the PAXgene Blood RNA 
Kit (IVD) for nucleic acid purification. The PAXgene Blood RNA System is intended for 
the isolation and purification of intracellular RNA for RT-PCR used in diagnostic testing. 
 
Peripheral Blood Mononuclear Cell (PBMC) 
The isolation of peripheral blood mononuclear cells (PBMC) from whole blood 
allows for the purification of immune system associated cells (Figure 3) [26]. These cells 
are able to respond to internal and external signals, and therefore have been proposed as a 
source of biomarkers of conditions and diseases, as their gene expression profile may 
reflect the physiological and pathological state of the organism. PBMCs are mainly 
comprised of monocytes, macrophages, T cells, B cells, natural killer (NK) cells, and 
dendritic cells (Figure 3). Thus, PBMCs contain different cell types that play important 
roles in the immune system such as monitoring immune-relevant events and response to 
inflammation [27]. The use of state-of-the-art proteomic profiling methods in PBMCs 
will enable minimally invasive monitoring of disease progression or response to 
treatment and discovery of biomarkers [27]. 
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Figure 3. Isolation of PBMC by Ficoll-Paque density gradient centrifugation: The bottom 
layer is made up of red blood cells (erythrocytes) collected or aggregated by the Ficoll 
medium and sink completely through to the bottom. The next layer up from the bottom is 
primarily granulocytes, which also migrate down through the Ficoll-Paque solution. The 
next layer towards the top is the PBMC, which are typically at the interface between the 
plasma and the Ficoll solution, along with monocytes and platelets. To recover the 
PBMC, this layer is carefully recovered, washed with a HBSS to remove platelets, Ficoll, 
and plasma, then centrifuged again. 
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HYPOTHESIS 
“NMT1 and METAP2 RNA transcripts are overexpressed in colorectal cancer patients’ 
peripheral blood mononuclear cells and whole blood samples and may translate into an 
effective biomarker for early detection of the disease and could possibly translate into a 
blood-based test for CRC screening.” 
 
OBJECTIVE 
The aim of the study is to investigate the patterns of gene expression of NMT1 and 
METAP2 in healthy control, non-adenomatous polyps, adenomatous polyps, and CRC 
patients’ whole blood and PBMC via the RT-PCR technique. 
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MATERIALS AND METHODS 
Whole blood study: RNA isolation with PAXgene® kit  
Blood samples from 18 participants including: 3 controls, 4 non-adenoma polyps, 
4 adenoma polyps, and 7 CRC patients were collected over the course of 1 year from 
September 2014 to April 2015. All participants went for colonoscopy at the Health 
Sciences Center (Winnipeg, Manitoba) and provided signed informed consent prior to 
their blood samples being obtained by venipuncture for accurate quantification of 
peripheral blood mRNA levels. A 2.5 ml sample of blood was transferred to a 
PAXgene™ tube for immediate cell lysis and nucleic acid precipitation. The mRNA is 
stable for up to 5 days in the blood lysate, provided the tubes are kept at room 
temperature until mRNA extraction. The PAXgene blood RNA kit (PreAnalytiX) was 
used for RNA extraction, according to the manufacturer’s protocol. 
 
PBMC study: RNA isolation using Ficoll-Hypaque gradient centrifugation 
Blood samples from 25 participants containing: 9 controls, 7 non-adenoma 
polyps, 6 adenoma polyps, and 3 CRC patients were collected from August 2017 to 
February 2018. All participants went for colonoscopy at the Health Sciences Center 
(Winnipeg, Manitoba) and provided signed informed consent prior to their blood samples 
being obtained by venipuncture for accurate quantification of peripheral blood mRNA 
levels. Blood samples were collected in EDTA tubes and PBMCs were isolated by Ficoll-
Hypaque gradient centrifugation. A Total RNA Kit was used for RNA extraction from 
PBMC (Omega Bio-Tek) according to the manufacturer’s protocol. 
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RNA Quantification 
The concentration and the purity of total RNA was measured using the ratio of 
absorbance at 260nm and 280nm (A260/A280) with a SpectraMaxR i3 spectrophotometer, 
and SoftMax software. The SpectraDrop Micro-Volume Microplate can confirm that the 
sample is free of protein (A260/A280) if the ratio ranges between 1.8 to 2.0.  
 
cDNA Synthesis:  Reverse Transcription of mRNA 
RNA samples were prepared for as follows: Total RNA (1 µg) was reverse-
transcribed using the iScript Reverse Transcription Supermix for RT-PCR (Bio-Rad) in a 
total volume of 20 µl according to the manufacturer’s instructions; The reaction mixture 
was incubated at 25 °C for 5 min for priming, then at 42 °C for 60 min for reverse 
transcription, and finally at 85 °C for 5 min for reverse transcriptase inactivation. The 
complementary DNA (cDNA) was stored at −20 °C until further use. 
 
Primers 
Quantitative PCR was performed on two target genes: NMT1 and METAP2; and three 
housekeeping genes: GAPDH, ACTB, and RPLP0. Information for all primers used is 
listed in Appendix T. 
 
Real Time Quantitative RT-PCR Analysis 
The expression of NMT1 and METAP2 was measured using RT-PCR. For 
amplification and data collection I used the CRX ConnectTM Real-Time System Cycler 
and CFX Manager 3.1 software (BioRad). The optimal reaction conditions were obtained 
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with 1x SsoAdvanced™ Universal SYBR® Green Supermix, 300 nM specific primer, 
RNase/DNase-free water, and cDNA template (20 ng/well) up to final volume of 15 
µl/well. Amplifications were performed starting with a 30 sec enzyme activation cycle at 
95 °C, followed by 40 cycles of denaturation at 95 °C for 5 sec, 1 cycle of 
annealing/extension at 60 °C for 30 sec, and a final cycle at 72 °C for 30 sec. At the end 
of each run a melting curve analysis was done from 65 °C to 95 °C for 0.5 to 5 sec. All 
samples were amplified in triplicates, and the obtained cycle of quantification (Cq) value 
was then used for further analysis. Cq values of >35 were excluded from further 
mathematical calculations. A NTC “no template sample” (RNA from reverse 
transcription without reverse transcriptase) and a sample without RNA or cDNA were the 
negative controls. 
 
Calculation of the amounts of gene expression 
The relative gene expression was calculated by the subtraction of the Cq value of NMT1 
(target gene) in the samples relative to GAPDH and ACTB (housekeeping gene) for 
whole blood samples. GAPDH and RPLP0 was the housekeeping gene for PBMC 
samples. Relative quantification is the most commonly used method [28]. 
 
Step 1. Normalize to (REF): ΔCq = Cq (Target gene) – Cq (Housekeeping genes) 
Step 2. Exponential expression transform: ΔCq Expression = 2(–ΔCq) 
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RESULTS  
1. NMT1 and METAP2 gene expression in Whole Blood 
Expression was measured by RT-PCR to examine the relative transcript levels of 
NMT1 and METAP2 in 18 patients, which consisted of healthy controls (n=3), non-
adenomatous polyps (n=4), adenomatous polyps (n=4), and CRC patient (n=7) whole 
blood samples (Figure 4 & 5). Analysis of the real-time RT-PCR results was performed 
by a relative quantification method whereby the change in expression of the target gene: 
NMT1 and METAP2 is determined relative to the average expression of GAPDH and 
ACTB housekeeping genes. 
 
Both NMT1 and METAP2 were detected in all the individuals (Figure 4 & 5). The 
overall expression of NMT1 and METAP2 was seen to be the highest in the non-
adenomas polyp samples with METAP2 being consistently higher than NMT1 (Figure 6). 
METAP2 and NMT1 expression patterns showed no significant differences in patient 
healthy control and non-adenomatous polyp samples. However, expression was the 
lowest in the healthy control compared to non-adenomatous polyps, adenomatous polyps 
and CRC (Figure 6). METAP2 expression was the lowest in the adenomatous polyp but 
increased by over 0.08-fold in control, 0.60-fold non-adenomatous polyps and 0.64-fold 
CRC patients (Figure 6). There was a significant increase in METAP2 in CRC whole 
blood samples. NMT1 showed a similar trend, expression was the lowest in the 
adenomatous polyp but increased by over 0.07-fold in control, 0.30-fold CRC and 0.58-
fold non-adenomatous polyp patients (Figure 6). There was a significant increase in 
METAP2 than NMT1 in CRC whole blood samples. 
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Figure 4. First set: Transcript levels of NMT1 and METAP2 from whole blood (PAXgene 
Tube), where Log 2 (Fold change) expression values shown on y-axis are calculated 
relative to GAPDH and ACTB. Control (C), non-adenomatous polyps (P), adenomatous 
polyps (AP), and CRC patients are shown on x-axis. 
 
 
Figure 5. Second set: Transcript levels of NMT1 and METAP2 from whole blood 
(PAXgene Tube), where Log 2 (Fold change) expression values shown on y-axis are 
calculated relative to ACTB. Control (C), non-adenomatous polyps (P), adenomatous 
polyps (AP), and CRC patients are shown on x-axis. 
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Figure 6. Transcript levels of NMT1 and METAP2 from whole blood (PAXgene Tube), 
where Log 2 (Fold change) expression values shown on y-axis are calculated by relative 
to the average housekeeping genes: GAPDH and ACTB. Control, non-adenomatous 
polyps, adenomatous polyps, and CRC patients are shown on x-axis. NMT1 and METAP2 
expression was lowest in adenomatous patients; however, NMT1 and METAP2 was the 
highest in non-adenomatous polyp and CRC patients. METAP2 was significantly higher 
than NMT1 in CRC patients’ whole blood sample. 
 
2. NMT1 and METAP2 gene expression in PBMC 
Expression was measured by RT-PCR to examine the gene expression of NMT1 
and METAP2 in PBMC samples from 25 patients, which consisted of healthy controls 
(n=9), non-adenomatous polyps (n=7), adenomatous polyps (n=6), and CRC patients 
(n=3) (Figure 7 & 8). Analysis of the real-time RT-PCR results was performed by a 
relative quantification method whereby the change in expression of the target gene: 
NMT1 and METAP2 is determined relative to the GAPDH and RPLP0 housekeeping 
genes.  
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The overall expression of NMT1 and METAP2 was higher in the non-
adenomatous polyps, adenomatous polyps, and CRC compared to healthy control 
samples (Figure 9). METAP2 expression was lowest in the healthy controls but increased 
by over 0.16-fold in CRC, 0.25-fold adenomatous polyps and 0.96-fold non-adenomatous 
patients (Figure 9). There was a significant increase in METAP2 in CRC whole blood 
samples. NMT1 showed a similar trend, expression was the lowest in the healthy controls 
but increased by over 0.34-fold in CRC, 0.30-fold adenomatous polyps and 0.95-fold 
non-adenomatous patients (Figure 9). There was a significant increase in NMT1 in CRC 
PBMC samples. 
 
Figure 7. First set: Transcript levels of NMT1 and METAP2 in PBMC isolated from 
whole blood sample using density gradient centrifugation (Ficoll), where Log 2 (fold 
change) expression values shown on y-axis are calculated relative to the GAPDH. 
Control (C), non-adenomatous polyps (P), adenomatous polyps (AP), and CRC patients 
are shown on x-axis. METAP2 and NMT1 was significantly lower in control patients. 
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Figure 8. Second set: Transcript levels of NMT1 and METAP2 in PBMC isolated from 
whole blood sample using density gradient centrifugation (Ficoll), where Log 2 (fold 
change) expression values shown on y-axis are calculated relative to the RPLP0. Control 
(C), non-adenomatous polyps (P), adenomatous polyps (AP), and CRC patients are 
shown on x-axis. METAP2 and NMT1 was significantly lower in control patients. 
 
 
Figure 9. Transcript levels of NMT1 and METAP2 in PBMC isolated from whole blood 
sample using density gradient centrifugation (Ficoll), where Log 2 (fold change) 
expression values shown on y-axis are calculated relative to the average GAPDH and 
RPLP0. Control, non-adenomatous polyps, adenomatous polyps, and CRC patients are 
shown on x-axis. NMT1 and METAP2 expressions was lowest in control patient however, 
NMT1 and METAP2 was the highest in patients with non-adenomatous polyp. METAP2 
was lower than NMT1 in PBMC in CRC patients. 
 18 
DISCUSSION 
 
N-myristoylation is a lipid modification found in mammalian, fungal, plant, and 
viral proteins. The enzyme mediating the protein myristoylation, N-myristoyltransferase 
(NMT), covalently attaches a 14-carbon fatty acyl group (myristoyl group) to a glycine 
residue at the N-terminus of a protein. The known myristoylated proteins include the 
catalytic subunit of cAMP-dependent protein kinase, various tyrosine kinases (pp60c-src), 
the β-subunit of calmodulin-dependent protein phosphatase (calcineurin), the 
myristoylated alanine-rich C-kinase substrate, and the α-subunit of several G proteins 
[23]. The myristoylated protein has multiple functions such as membrane localization, 
protein translocation, and oncogenesis.  
 
In general, protein myristoylation is a co-translational process that occurs after the 
removal of methionine by methionine aminopeptidase (MetAP). Methionine 
aminopeptidase 2 (MetAP2) is a bifunctional protein that plays a critical role in the 
regulation of post-translational processing and protein synthesis. The main aim of this 
study was to investigate the gene expression of NMT1 And METAP2 in whole blood and 
PBMC in HSC patients by Real Time RT-PCR methods. RT-PCR was chosen because it 
is highly specific, sensitive, and can detect the gene expression of multiple genes at one 
time. Moreover, it is one of the most reliable methods of quantifying mRNA and is 
therefore well-suited to the application of helping to triage patients who are waitlisted for 
colonoscopy and is a favorable option for the analysis of cancer markers [29].  
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I quantitatively evaluated the expression profile of 2 target genes: NMT1 and 
METAP2 in both whole blood and PBMC from healthy controls, non-adenomatous 
polyps, adenomatous polyps, and CRC patients. Here we show that both NMT1 and 
METAP2 were overexpressed in PBMCs from the CRC patients. This result demonstrated 
that both the enzymes NMT and MetAP play a major role in the process of 
myristoylation of oncoproteins, and more glycine terminal protein is required by the cells 
for proliferation and cancer development. When both genes were compared, METAP2 
expression was found to be higher than NMT1 and it was significantly more prevalent in 
CRC. The high expression of METAP2 in human colorectal carcinoma, revealed the 
potential role of MetAP2 in cancer. The high level of METAP2 activity in colon cancer 
correlates with both an increase in enzyme synthesis and an association of the activated 
kinase with the cytoskeleton. MetAP2 is also known as the molecular target of the 
angiogenesis inhibitor TNP-470 [30]. There been reports that a high level of MetAP2 
expression was observed in B cells of malignant lymphomas [31].  
 
All the samples had similar gene expression except in adenomatous polyps from 
the whole blood and PBMC. In whole blood, NMT1 gene expressed higher than 
METAP2, but in PBMCs the NMT1 expressed lower than METAP2. The discrepancy in 
expression profile of NMT1 and METAP2 in whole blood and PBMC suggest that cells 
other than PBMC such as neutrophils have different pattern of expression for these genes. 
In an earlier study by Shrivastav et al have shown that neutrophil upon activation display 
differential expression of NMT1 compared to resting neutrophils.  
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Real-time PCR approaches are now widely applied in clinical research to quantify 
the abundance and expression of functional gene markers in biological samples. 
However, RT-PCR has significant limitations. Traditionally, false-positives due to 
carryover contamination have caused considerable problems in the routine 
implementation of qPCR in research and have led to strict guidelines in the design of 
laboratories dedicated to performing PCR. RT-PCR workflow has multiple steps, and 
there can be several sources of bias in gene measurement by RT-PCR that can alter the 
results. In the initial step, RNA extraction, excess use of 95% ethanol can crosslink RNA, 
and the presence of polysaccharides can reduce the elution of RNA. During the second 
step, in which the RNA is converted to cDNA, the presence of reverse transcriptase 
inhibitors can result in the incomplete conversion of all the RNA present into cDNA. The 
presence of inhibitors can significantly increase the measurement biases, and produce 
false negative or false positive results in both RT-PCR and cDNA reverse transcription. 
 
        An alternative to PCR is western blot analysis - a technique in which the 
activation of proteins in signaling pathways can be detected. Western blots can be used to 
study the protein expression of NMT1 and MetAP2. This method is sensitive and 
specific, and inexpensive compared to PCR. Another alternative to qPCR is 
immunofluorescence. Used observe the expression and localization on NMT1 and 
MetAP2 in PBMCs, this method is both quicker and inexpensive relative to PCR and 
Western blots Analysis. 
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Overall, RT-PCR is an excellent tool that may assist in the understanding of the 
molecular events underlying human cancer. An accurate RT-PCR analysis could improve 
clinical diagnosis as well as predictive and prognostic monitoring of disease. 
Furthermore, RT-PCR may offer tools to detect and measure gene expression at an early 
stage. The results demonstrate that when a patient’s blood is over-expressing NMT1 or 
METAP2, they should be prioritized and screened for colorectal cancer. Screening can 
prevent colorectal cancer by finding and removing polyps before they turn into cancer. 
Early detection will result in a greater number of treatment options and better outcomes. 
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CHAPTER 2:  
Functional Relevance of N-myristoyltransferase 1 in Cellular Growth Pathway 
 
Mouse Embryonic Stem Cells 
Mouse embryonic stem cells (mESC) are self-renewing, pluripotent cells derived 
from the inner cell mass of blastocyst stage mouse embryos. mESC, spontaneously 
differentiate into numerous cell types derived from all three embryonic germ layers [32]. 
Stem cells can be classified into three broad categories, based on their ability to 
differentiate. Totipotent stem cells are found only in early embryos. Each cell can form a 
complete organism (e.g., identical twins). Pluripotent stem cells exist in the 
undifferentiated inner cell mass of the blastocyst and can form any of the over 200 
different cell types found in the body [33]. Multipotent stem cells are derived from fetal 
tissue, cord blood and adult stem cells [32]. Although their ability to differentiate is more 
limited than pluripotent stem cells, they already have a track record of success in cell-
based therapies. 
 
NMT and ESC 
As is known, the N-myristoylation process is catalyzed by the enzyme N-
myristoyltransferase. N-Myristoylated proteins comprise a large family of functionally 
diverse eukaryotic and viral proteins. Proteins that are destined to be covalently modified 
with the 14-carbon saturated fatty acyl group (myristoyl group) generally contain the 
sequence Gly–X–X–X–Ser/Thr at the amino terminus (Figure 2). The significance of 
NMT in normal cellular functioning is evident from a study where Drosophila embryos 
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with null NMT mutations displayed a range of abnormal phenotypes, including failure of 
head involution, dorsal closure, and germ-band retraction, all of which are strikingly 
similar to phenotypes caused by mutations to genes involved in dynamic rearrangement 
of the actin cytoskeleton. As just stated above, together with the recent demonstrations 
that showcase that the myristoylated non-receptor tyrosine kinases, Dsrc42A and 
Dsrc64B, are key regulators of cytoskeletal dynamics [34, 35], support the idea that 
myristoylated proteins have important functions in fundamental morphogenetic processes 
in Drosophila [36]. NMT in lower eukaryotes is encoded by a single NMT gene, whereas 
in higher eukaryotes such as bovines, humans, and plants, NMT is encoded by two NMT 
genes located on separate chromosomes. The second genetically distinct NMT cDNA 
(NMT2) has been cloned from a human liver library [37].  
 
Since, NMT1 and METAP2 were found to be overexpressed in whole blood and 
PBMC of individuals with polyps and CRC, I wanted to further investigate the role of 
NMT1 in signaling proteins especially those of metabolic pathway which are known to 
be perturbed in CRC [38]. Furthermore, previous findings from our group suggest NMT1 
is crucial for mouse embryo development and myelopoiesis. By knocking out the Nmt1 
gene in mice, it was demonstrated that NMT1 is the principal enzyme in early 
embryogenesis. Inter-crosses of Nmt1+/- mice yielded no viable homozygotes (Nmt1-/-). 
Since Nmt1-/- Embryonic Stem cells (ES Nmt1-/- KO) could be isolated, NMT1 does not 
appear to be essential for viability of mammalian cells, but it is required for the early 
embryonic development. Although both NMT isoforms share 77% amino acid sequence 
homology, they differ in substrate affinity [39]. NMT1 has been acknowledged to be the 
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principal isoform responsible during early embryogenesis of mice [40]. It has also been 
reported that NMT1 and regulated total NMT activity is essential for proper monocytic 
differentiation [41] and, using bovine neutrophils, it was demonstrated that NMT1 has a 
role in regulating neutrophil lifespan [42].  
 
As demonstrated in the chapter 1, NMT1 and METAP2 genes were overexpressed 
in peripheral blood or PBMC of individuals with polyps and CRC. Based on previous 
reports where NMT1 has been demonstrated to be the downstream target of Akt [43], I 
was interested in investigating the effect of NMT1 knockout on PI3K/Akt/mTOR 
signaling pathway. 
 
PI3K/Akt/mTOR Signaling Pathway 
The PI3K/Akt/mTOR pathway is an important intracellular downstream pathway 
that regulates cellular growth, cell proliferation over differentiation (stem cells/ neural 
stem cells), protein synthesis, and apoptosis (Figure 2) [44]. Once this pathway is 
activated, it can propagate to downstream substrates including: receptor tyrosine kinases 
(RTK), PI3K, Akt/PKB, mammalian target of rapamycin (mTOR), and NMT. When this 
pathway is overactive, it can increase cell proliferation and inhibit apoptosis [45]. In 
order to activate this pathway, insulin or insulin-like growth factors must bind to the 
insulin-like growth factor-1 receptor (IGF-1R), which is a receptor tyrosine kinase 
(RTK). RTKs are composed of 2 extracellular alpha-subunits and 2 transmembrane beta 
subunits. This pathway is first initiated by insulin binding to the alpha-subunits of the 
RTK [46], [47]. Insulin binding causes autophosphorylation of the RTK beta subunits 
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that transduces downstream regulators and triggers phosphorylation of multiple 
substrates. Insulin receptor substrate 1 (IRS-1) is the first intracellular substrate of the 
RTK following autophosphorylation [45, 48]. This results in the activation of IRS-1 
docking proteins, followed by PI3K. PI3K is composed of two subunits; one subunit 
houses two SH2 domains and another serves as a catalytic domain [49]. The PI3K 
substrate becomes activated by phosphorylation at the SH2 domain [49]. The activated 
protein approaches phosphatidylinositol-4,5,-bisphosphate (PIP2), converting this 
phospholipid to phosphatidylinositol-3,4,5,-trisphosphate (PIP3). The activation of 
Akt/PKB is facilitated by its binding to PIP3, which in turn exposes the residues Ser473 
and Thr308 [45, 48]. To fully activate Akt, phosphoinositide-dependent kinase 1 (PDK-1) 
phosphorylates Akt at Thr308 and mTOR-rictor complex 2 phosphorylates Ser473. 
Activated Akt translocates to the cytoplasmic region to control mTOR phosphorylation. 
 
Figure 10. The PI3K/Akt/mTOR pathway plays an essential role in cell proliferation. 
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i. Regulation of mTOR: mTOR is a serine/threonine kinase that regulates protein 
synthesis and cell proliferation through phosphorylation of its downstream targets [45, 
50]. Recent biochemical and genetic studies have demonstrated that mTOR exists in two 
different complexes referred to as mTOR-raptor complex 1 (mTORC1) and mTOR-rictor 
complex 2 (mTORC2). mTORC1 positively regulates cell proliferation, autophagy, and 
protein synthesis. mTOR activation following RTK stimulation can result in 
phosphorylation and activation of ribosomal protein S6 kinase (S6K), which leads to 
activation of S6 transcription factors. mTORC2 plays a key role in various biological 
processes, including: metabolism, cytoskeleton organization, and phosphorylation of Akt.  
 
ii. Dysregulation of mTOR: mTOR plays a central role in the regulation of cell growth 
and proliferation. One downstream target of mTOR is p70S6K, which then leads to the 
phosphorylation of 40S ribosomal S6 to initiate translation of mRNA [51], [52]. 
Dysregulation of mTOR activity manifests as abnormal cell growth. A protein that can 
decrease activity of mTOR is PTEN [53]. PTEN is a tumor suppressor that functions as a 
dual-specificity lipid and protein phosphatase that inhibits cell proliferation and the 
inactivation of other tumor suppressors. By dephosphorylation of PIP3 into PIP2, PTEN 
negatively regulates PI3K/Akt signaling and subsequent downstream pathways [51]. 
Regulating the PI3K/Akt/mTOR signaling pathway has been shown to be pivotal to 
prostate cancer proliferation and the pathogenesis of an advanced disease [54], [55]. 
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NMT Activity in PI3K/Akt/mTOR pathway 
NMT modifies proteins by covalently attaching a myristoyl group to their N-
terminus. Activation of Akt/PKB, a central hub protein of the insulin signaling pathway, 
leads to the phosphorylation of NMT1. Our lab has previously shown that the mTOR and 
NMT based pathways are interlinked since NMT has been demonstrated to myristoylate 
mTOR and mTOR phosphorylates NMT. 
Rapamycin Treatment 
Rapamycin (Sirolimus) is a macrocyclic antibiotic that is produced by bacteria 
called Streptomyces hygrocopius (Figure 11) [56]. It is used as an immunosuppressant, 
and its analog, RAD001, delays cell proliferation. Rapamycin and the rapalogue, 
RAD001, are used as tumor suppressive drugs in cancer treatments and are used as 
immunosuppressive drugs during organ transplants [56]. Rapamycin is known to inhibit 
mTOR, thus blocking the activity of its downstream targets (Figure 12). mTOR directed 
inhibition can take place via one of two mechanisms, competitive ATP-subunit inhibitors, 
or uncompetitive allosteric inhibitors. Rapamycin is an allosteric inhibitor that first binds 
with the intracellular receptor FKB12 and targets the FRB (FKBP12/rapamycin-binding) 
domain of mTORC1[56]. mTOR forms two major complexes: mTORC1, and mTORC2. 
The mTORC1 consists of mTOR, Raptor, mLST8, FKBP38, PRAS40, and Deptor. 
Compared to mTORC2, rapamycin inhibition is extremely selective for mTORC1. In 
early studies of mTOR, rapamycin was used almost entirely to describe the functions of 
mTOR, which it inhibits [57]. The inability of rapamycin and other rapalogues to inhibit 
mTORC2 has contributed to the lessened understanding regarding the cellular functions 
of this complex.  
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Figure 11. Rapamycin is a macrocyclic antibiotic that inhibits the highly conserved 
protein kinase target of rapamycin (TOR) by forming a complex with FKBP12, which 
then binds directly to mammalian TOR complex 1 (mTORC1) and inhibits mTOR 
pathway. 
 
The proposed mechanism of rapamycin inhibition is postulated to be through the 
destabilization of the mTOR-raptor binding, resulting in the destabilization of the 
mTORC1 complex [56]. The major issue with inhibiting mTORC1 as a method of cancer 
treatment is the inherent nature of the negative feedback loop it controls. mTORC1 
inhibition may lead to the development of an mTORC1 independent growth pathway 
with an upregulation of Akt, due to failure of inhibiting IRS-1/2 activity [58]. Mitigating 
strategies have been developed, such as using dual mTOR and PI3K inhibitors, and ATP-
competitive inhibitors that inhibit both mTORC1 and mTORC2 have been developed as 
alternative cancer treatments [56]. 
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Figure 12. Rapamycin binds the intracellular receptor, interfering with growth-promoting 
cytokine signaling. This is done through inhibition of mTOR autophosphorylation and 
phosphorylation of initiation factor 4E binding protein, 4EBP1, which plays an important 
role in translation. 
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HYPOTHESIS 
NMT1 regulates metabolic pathways. 
OBJECTIVE 
To investigate the effect of NMT deficiency on metabolic pathway. 
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MATERIALS AND METHODS 
Generation of Heterozygous (Nmt1+/-) and Homozygous (Nmt1-/-) – deficient ES cells 
Nmt1-deficient (Nmt1+/- and Nmt1-/-) ES cells were generated as described previously 
[59]. In brief, a mouse ES cell line (XE400, strain 129/Ola) with an insertional mutation 
in the Nmt1 gene was created in a gene-trapping program, BayGenomics 
(baygenomics.ucsf.edu). 
Isolation of Heterozygous (Nmt1+/-) and Homozygous (Nmt1-/-) – deficient ES cells  
Nmt1-deficient ES cells were isolated as previously described [59].  In brief, Nmt1 
mutant ES cells were grown for 24 h in ES cell medium in a 100-mm gelatin-coated petri 
dish. Single colonies were picked and grown under G418 selection pressure (20 mg/ml). 
Nmt1 mutant ES cells were validated by Western blotting and RT-PCR. 
ESC Cell culture 
Wild type (WT) and Nmt1-deficient ES cell lines were cultured in Glasgow 
minimum essential medium (GMEM) (Sigma-Aldrich) supplemented with 2 mM 
glutamine (Invitrogen Life Technologies), 1 mM sodium pyruvate, 1X nonessential 
amino acids, 10% (v/v) FBS, a 1/1000 dilution of 2-mercaptoethanol (ME) of stock 
solution, 500 Units/ml LIF (Leukemia Inhibitory Factor) in a 100-mm gelatin coated 
Petri dish. Cells were cultured at 37 °C/5% CO2. For metabolic pathway analysis, ES 
cells were seeded in gelatin coated T25 culture flasks and cultured overnight at 37 °C in a 
CO2 incubator. One day prior to ES cell stimulation, ES cells were serum starved 
overnight, followed by 10 nM insulin and 10 nM rapamycin treatment. ES cells were 
cultured in the presence or absence of treatments for the indicated time points, after 
which the cells were washed with ice cold 1X PBS. Thereafter, cell pellets were collected 
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and incubated in lysis buffer (50mM HEPES (pH 7.4), 150mM sucrose, 2 mM sodium 
orthovanadate, 10 mM sodium fluoride, 10 mM sodium pyrophosphate, 2 mM EGTA, 2 
mM EDTA, 1% triton X-100, and 0.1% SDS), supplemented with 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 1% protease inhibitor cocktail for 10 minutes 
on ice. After incubation, the pellets were centrifuged at 1600 rpm for 5 minutes. The 
supernatant was collected and stored at -20 °C until further analysis. 
Western Blotting’s 
Adherent cells ESC were washed with PBS on ice, and then lysed with ice-cold 
1% SDS lysis buffer. The Bicinchoninic acid (BCA) kit (Pierce) was used to estimate 
protein concentration (all in duplicate) of cell lysates according to the manufacture’s 
protocol. Protein concentration was read by measuring absorbance at λ = 560 nm on a 
Multiskan Ascent (Thermo Electron Corporation) plate reader. Thirty µg of protein was 
mixed with SDS-PAGE sample buffer (0.2M Tris-HCl pH 6.8, 40% glycerol, 8% SDS, 
and 0.04% bromophenol blue) and heated at 95 °C for 5 mins. The samples were resolved 
on a 10% polyacrylamide gel ran on SDS-PAGE buffer in a Bio-Rad Mini-Protean Tetra 
cell. Samples were run through the stacking gel at 100 V until the samples lined up at the 
top of the stacking gel and then the voltage was increased to 150 V. The proteins were 
transferred onto a PVDF membrane (Biorad) at 120 V for 90 minutes. The membrane 
was incubated for an hour with blocking solution (5% non-fat dry milk dissolved in 1X 
PBS-containing 0.02% Tween 20) at room temperature. Blots were probed with specific 
polyclonal rabbit antibodies against PI3K p100α, phosphorylated Akt, AMPK, mTOR, 
GSK and IGF1R diluted (1:1000) in 5% milk-PBST, overnight at 4 °C. The membrane 
was then washed in PBST three times for 10 min each followed by incubation with 
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suitable secondary antibody (1:2000) conjugated with horseradish peroxidase for 1 hour 
at room temperature. The membrane was washed in PBST three times for 10 min each; 
visualization was done using ClarityWestern ECL substrate (Bio-Rad) reagent and a 
Molecular Imager® ChemiDoc™ XRS System (Bio-Rad) and Image Lab™ software 
Version 3.0. Thereafter, the blots were routinely stripped and re-probed with antibodies 
against total Akt, AMPK, mTOR, GSK and IGF1R. that were used as loading controls. 
Densitometric analysis was performed and integrated density values were presented as 
ratio of phosphorylated protein over total compared with WT control. 
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RESULTS 
1. NMT1 protein expression is completely abrogated in Nmt1-/- ESC  
In order to study the mechanism by which NMT1 activity impacts metabolic 
pathway, Nmt1-/- KO cells were developed as described in materials. The successful 
ablation of Nmt1 was validated by qPCR and Western blot analysis [41]. Western blot 
analysis revealed the complete absence of NMT1 protein expression in homozygous KO 
cells and almost 50% ablation in heterozygous cells whereas β-actin, which was used as 
the loading control, was similar in Nmt1+/+, Nmt1+/- and Nmt1-/- KO ES cells. Relative 
normalized Nmt1 gene expression was assessed by RT-PCR in Nmt1+/- ES, Nmt1-/- and 
WT ES cells (Figure 13B). We also validated NMT1 protein expression using both 
commercially available antibodies and custom monoclonal antibodies raised in a murine 
system (Figure 13A).  
 
Figure 13. NMT1 protein expression by Western blot was assessed in WT ES and Nmt1-/- 
ES cells by different antibodies (Figure 13A). Relative normalized Nmt1 gene expression 
was assessed by RT-PCR in Nmt1+/- ES, Nmt1-/- and WT ES cells (Figure 13B). 
 
 
2. PI3K p110α expression is up-regulated in Nmt1-/- ESC 
Growth factors such as insulin, epidermal growth factors, nerve growth factors 
and platelet derived growth factors bind to cell surface transmembrane receptors 
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belonging to the RTK superfamily and regulate metabolic pathways. A major 
downstream hub of I/IGF1R pathway is PI3K/Akt, therefore, the effect of NMT1 ablation 
was investigated on metabolic pathway regulated by PI3K/Akt compounded with the fact 
that NMT1 is a downstream target of Akt [43]. For this, I used embryonic stem (ES) cells 
from Nmt1-/- knockout mice, and these cells were subjected to different treatments to 
modulate insulin signaling.  The ES cells were treated with insulin to activate the RTK 
and its downstream target proteins, and with rapamycin to inhibit mTOR. Thereafter, a 
combination of rapamycin pretreatment, followed by insulin treatment was also given to 
assess the effect of mTOR inhibition on the activation of RTK and downstream targets. 
The phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (p110α) is a 
major regulator of PI3K/Akt pathway; therefore, I first investigated the effect of Nmt1-/- 
knockout on p110α expression. As shown in Figure 14, NMT1 WT ES cells showed 
p110α basal expression and different treatments had no effect on the basal expression. 
However, Nmt1-/- ES cells showed increased p110α expression, and activation of the 
pathway with insulin or rapamycin further enhanced p110α expression. The same 
membrane was probed with anti-NMT1 antibody to confirm that Nmt1-/- ES cells were 
deficient in NMT1. Figure 14C shows the NMT1 expression in WT and Nmt1-/- ES cells 
in the same blot that was probed with Akt. 
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Figure 14. Nmt1-/- ES cells show increased PI3K p110α expression. WT ES and Nmt1-/- 
ES cells were treated with rapamycin (10 nM) and/or insulin (100 nM) for 24 hrs. The 
cells were lysed and the lysates were assessed by Western blot for the expression of the 
catalytic subunit of PI3K, p110α (Figure 14A). The right panel shows the corresponding 
densitometry (Figure 14B). The same membrane was stripped and reprobed with NMT1 
(Figure 14C). 
 
 3. Akt phosphorylation is up regulated in Nmt1-/- ES cells compared to WT ESC 
Previously it has been demonstrated that overexpression of Akt/PKB resulted in 
the phosphorylation of NMT1 in breast cancer cells [60] establishing NMT1 as a 
downstream target of Akt. Therefore, I determined the effect of different treatments on 
the phosphorylation of Akt in WT and Nmt1-/- ES cells. As shown in (Figure 15A), WT 
ES cells showed decrease in the phosphorylation of Akt compared to Nmt1-/- ES cells. 
Interestingly, phosphorylation of Akt at Ser473 was significantly upregulated upon 
treatment with insulin alone in Nmt1-/- KO cells.  
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Figure 15. Akt and GSK phosphorylation was upregulated in Nmt1-/- ES cells upon 
insulin treatment. WT ES and Nmt1-/- ES cells were treated with rapamycin (10nM) 
and/or insulin (100nM) for 24 hrs. The cells were lysed and the lysates were assessed by 
western blot for the phosphorylation of Akt (Figure 15A) and GSK3 (Figure 15C). The 
same blots were stripped and re-probed with Abs against total Akt and GSK3 and used as 
loading controls. The right panel shows the corresponding densitometry (Figure 15B and 
15D). The Western blot results represent one of three independent experiments with 
similar findings. 
 
4. GSK phosphorylation is up regulated in Nmt1-/- ES cells compared to WT ESC 
Remarkable up-regulation of p110α and AKT in Nmt1-/- KO ES cells prompted 
me to further investigate two key regulators of metabolic pathways – glycogen synthase 
kinase 3 (GSK3) and mTOR (Figure 15). Although GSK3 was initially identified in the 
regulation of glycogen synthesis, it has been shown that GSK3 plays a role in a wide 
range of cellular processes particularly in cancer [61]. The GSK3 gene family has two 
highly conserved kinases including GSK3 α and GSK3 β. Both kinases are structurally 
similar but not identical in terms of their functions [61]. Figure 15D shows the expression 
of GSK 3 α /β. GSK3 α /β. phosphorylation was upregulated upon treatment with insulin 
alone or in combination with rapamycin in Nmt1-/- ES cells compared to WT cells.  
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5. mTOR phosphorylation is up regulated in Nmt1-/- ES cells compared to WT ESC 
mTOR is a downstream target of the PI3K/Akt pathway and is the central regulator of 
protein synthesis and metabolism [62]. Therefore, we determined the expression of total 
mTOR and its phosphorylation at the Ser2448 residue (Figure 16A). In WT ES cells, the 
total mTOR expression did not change upon treatment with insulin and/or rapamycin. 
However, the phosphorylation of mTOR Ser2448 was downregulated upon rapamycin 
treatment in WT cells whereas the mTOR phosphorylation was greater in Nmt1-/- ES cells 
and was further enhanced upon treatment with insulin. In line with what I observed for 
other PI3K pathway proteins, NMT1 deficiency is associated with increased mTOR 
phosphorylation. 
 
6. Nmt1-/- ES cells show increased IGF1R phosphorylation compared to WT ESC 
Insulin like growth factor 1 and 2 binds to type 1 insulin like growth factor 
receptor and activates the downstream signaling pathways. Insulin receptor substrates 
IRS1 and IRS2 are the main adaptors that act as docking sites and link the activated 
receptors to various intracellular adaptor proteins and downstream signaling cascades 
including PI3K/Akt signaling cascades [63, 64]. Insulin-like growth factor is important in 
mammary development and IGF1R is required for mammary gland morphogenesis. 
Although IGF1 plays a critical role in cell growth, survival and migration several studies 
have shown that alterations in the IGF signaling results in the development and 
progression of multiple cancers. Since increased p110α expression and increased 
phosphorylation of Akt and mTOR were observed due to NMT1 ablation, I wanted to 
investigate whether the IGF1R phosphorylation is affected in WT and in Nmt1 -/- ES cells. 
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Therefore I treated both, the WT and Nmt1-/- ES cells, with insulin and rapamycin and 
assessed the phosphorylation. Interestingly, IGF1R phosphorylation was upregulated in 
the Nmt1 -/- ES cells compared to WT cells (Figure 16C). 
 
Figure 16. mTOR and IGF1R phosphorylation was upregulated in Nmt1-/- ES cells 
compared to WT cells. WT ES and Nmt1-/- ES cells were treated with rapamycin (10nM) 
and/or insulin (100nM) for 24 hrs. The cells were lysed and the lysates were assessed by 
Western blot for the phosphorylation of mTOR (Figure 16A) and IGF1R (Figure 16C). 
The same blots were stripped and re-probed with Abs against total mTOR and IGF1R and 
used as loading controls. The right panel shows the corresponding densitometry (Figure 
16B and 16D). The Western blot results represent one of three independent experiments 
with similar findings.  
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7. AMPK phosphorylation is upregulated in WT cells compared to Nmt1-/- ESC 
AMP activated protein kinase (AMPK) is a heterotrimeric enzyme consisting of 
one catalytic subunit and two regulatory subunits.  Reports have shown that AMPK 
regulates IRS1 and Akt whereas insulin and Akt are shown to have negative impacts on 
AMPK activation [65-67]. In Figure 17, we were interested to see the effect of NMT1 
deficiency on AMPK phosphorylation. Unlike the other signaling molecules, AMPK 
phosphorylation was upregulated in WT cells compared to Nmt1 -/- ES cells. 
 
Figure 17. AMPK phosphorylation was upregulated in WT ES cells compared to Nmt1-/-
ESC cells. 
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DISCUSSION 
N-myristoylation is an important protein modification that regulates protein 
function and localization. Myristoylated proteins have shown to be involved in various 
cellular processes, including cellular proliferation and oncogenesis [13]. Evidence from 
various studies suggests the involvement of NMT in cancer development and progression 
[25]. In the present study, I attempted to identify whether NMT deficiency has any 
impact on the PI3K-Akt signaling pathway. Several reports have shown that the PI3K-
Akt signaling pathway proteins involved in cell growth and differentiation undergo 
oncogenic changes and are altered in various human cancers. This pathway plays a 
critical role in tumor development as well as in the potential response of tumor to cancer 
treatment. 
 
The results of this study identify for the first time how the deficiency of NMT1 
affects the key PI3K-Akt pathway signaling proteins. The class IA PI3K forms an 
important node in the insulin metabolic pathway. It was observed that in the absence of 
NMT1, p110α protein expression was upregulated and all subsequent downstream targets 
such as Akt, mTOR, GSK3 and IGF1R phosphorylation was also increased following 
insulin treatment.  
 
The Wilm’s tumor 1 protein (WT1) has been shown to be a transcriptional 
regulator that can either activate or repress transcription of key growth factors [68]. WT1 
functions as an activator on its own, but its binding to the BASP1 corepressor shifts WT1 
activity to a state of transcriptional repression [69]. BASP1 has been identified as a WT1-
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binding protein, which mediates the transcriptional repression activity of the latter [70]. 
Translocation of transcription factors is important for the regulation of gene expression. 
Many transcription factors, such as BASP1 are myristoylated and several studies have 
shown that BASP1 is stoichiometrically N-terminally myristoylated in different tissues 
[71]. Myristoylation is required for the binding of BASP1 to WT1 [69]. It has been 
demonstrated that IGF1R gene expression is regulated by WT1 [72], which indirectly 
suggests the possibility of NMT1 involvement in IGF1R gene expression/regulation. 
When BASP1 and WT1 are joined in a complex, WT1 acts as a transcriptional repressor 
that inhibits IGF1R gene expression. This increase in IGF1R gene expression could be 
the reason for over activation of the IGF1R signaling pathway proteins observed in Nmt1-
/- ES cells. 
 
I observed that NMT1 deficiency has a direct effect on overall protein expression 
(Figures 7-9). NMT1 deficiency resulted in the activation of PI3K/AKT pathway upon 
treatment with Rapamycin and Insulin. GSK3 has been shown to regulate the activities of 
certain transcription factors such as NF-kappaB, Snail, Notch and CAAT-enhancer 
binding protein (C/EBP) [73-75]. Even after several years of research, the role of GSK3 
in cancer remains complex and controversial. GSK3 has shown to be overexpressed in 
various cancers including that of colon, liver, ovarian and pancreatic tumors [76-78]. Our 
results show an increase in GSK3 phosphorylation in Nmt1-/- ES cells compared to WT 
cells, suggesting that in the absence of NMT1, no myristoylation occurs and therefore 
there is no complex formation between BASP1 and WT1, which in turn leads to 
increased IGF1R expression due to the lack of repressor activity. 
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CONCLUSION 
 
In summary, a precise balance between growth promoting signals and growth 
inhibitory signals plays important roles in the maintenance of healthy cells. Any 
dysregulation of this critical balance converts normal cells into abnormal or cancerous 
cells. In chapter one, RT-PCR analysis show that NMT1 and METAP2 transcripts are 
overexpressed in CRC patients’ whole blood and PBMC. Both NMT1 and METAP2 were 
the highest in CRC compared to healthy controls, non-adenomatous polyps, and 
adenomatous polyps. In addition, an increase in METAP2 than NMT1 activity appeared in 
adenomatous polyp. The results of my study provide insight into effect of NMT1 and 
METAP2 overexpression on immune response PBMC as they play important role in 
tumor progression. Therefore, METAP2 can be used as a potential marker for the early 
detection of colorectal cancer. These observations lead to the possibility of developing 
MetAP2 specific inhibitors, which may be therapeutically useful. RT-PCR method is a 
convenient, more accurate and cost-effective screening test that could triage patients for 
more intensive procedures such as colonoscopy. The outcome of my study could lead to 
development of an efficacious screening test for CRC. 
 
 
In the last chapter, Western blot analysis revealed that ESC Nmt1-/- KO has an 
over activation of the PI3K/Akt pathway compared to WT ESC. This pathway is essential 
for cellular growth, and cell proliferation. In the absence of NMT1, the downstream 
targets: p110α subunit of PI3K, Akt, GSK3, mTOR, and IGF1R were all upregulated. 
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However, AMPK levels were downregulated in NMT1-/- ES cells. In addition to Western 
blots, I observed the ESC Nmt1-/- KO cell line was proliferating faster than WT. NMT1 is 
vital for proper function cell division. The macroscopic result reveals that when NMT1 
not present, the P13K/Akt pathway is overactive and induce cell proliferation. It is 
possible that overexpression of NMT1 in PBMC of individuals with polyps and CRC 
may be one of the reasons for their lower PBMC proliferation [79]. 
 
Overall, the results from RT-PCR and Western blot demonstrate development of 
rational combinations, driven by compelling preclinical data and matched to genetic 
drivers in patients. This study has the potential to significantly improve the future care of 
cancer patients. The outcome of my study would lead to the development of an 
efficacious screening test for CRC. 
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APPENDICES 
Appendix  A: To maintain ESC media 
Cell Type LIF (10ng/ml) = 5 µl G418 (50mg/ml) = 20 µl 
ESC wild-type Yes No 
ESC Nmt1-/- KO  Yes Yes 
 
Western Blot Assay 
Treatment Concentration 
DMSO 10nM 
Rapamycin 10nM 
Insulin 100nM 
 
To dilute 2-Mercaptoethanol Stock Solution 
For ESC media (GMEM media) 
35ul (2-mercaptoethanol) + 10ml (Ultrapure Distilled Water RNase and DNase free) 
 
To make incomplete 1L of ESC Media (check if L-glutamine is added) 
1. 12.5g (GMEM powder) 
2. 2.75g (Sodium Bicarbonate NaHCO3) 
3. 800ml (Distilled Water) 
4. Adjust pH 7.2-7.4 
5. Add the remaining distilled water, Final volume = 1L 
6. **Note make 5L instead of 1L** 
Filter Sterilize: using a 2 micron vacuum filter before use 
To make Complete 1L of ESC Media 
1. 900ml (Incomplete-GMEM media) 
2. 10ml (Sodium Pyruvate 100mM) à 1mM 
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3. 10ml (Non-essential amino acid 100X) à 1X 
4. 100ml (FBS: Fetal bovine serum) à 10% 
5. 1ml (B-mercaptoethanol Stock Solution) à 1:1000 
6. 5ul (LIF 10ng/ml) per 10ml media 
7. 20ul (G418 50mg/ml) only for ESC Homo 
 
 
 
Appendix  B: 0.05% Trypsin-EDTA (5mL) 
• 1 mL 0.25% Trypsin-EDTA (1X), Phenol Red 
• 4mL phosphate buffered saline 
 
Appendix  C: PBS (10X) (1 Litre) 
• 80 g NaCl 
• 2 g KCl 
• 14.4 g Na2HPO4  
• 2.4 g KH2PO4  
• Dissolve all components in 800 mL R/O water 
• Adjust pH to 7.4 using HCl or NaOH and bring final volume to 1000 mL 
 
Appendix  D: Lysis Buffer Preparation for Phosphoproteins (500 mL) 
• 50 mM HEPES (pH 7.4)  (5.975 g) 
• 150 mM sucrose (25.67 g) 
• 2 mM sodium orthovanadate (5 mL from 200 mM stock)* 
• 80 mM glycerophosphate (12.24 g) 
• 10 mM sodium fluoride (0.21 g) 
• 10 mM sodium pyrophosphate  (2.23 g) 
• 2 mM EGTA (2 ml from 0.5M stock)** 
• 2 mM EDTA (2 ml from 0.5M stock)*** 
 52 
• 1% TritonX-100 (5 mL)  
• 0.1% SDS (0.5 g) 
• 20 µl Phenylmethylsulfonyl fluoride (100 mM)**add fresh to 1 mL lysis buffer  
• 20 µl protease inhibitor cocktail – add fresh to 1 mL lysis buffer  
 
*Activation of sodium orthovanadate (Na3VO4) 
(to achieve maximal inhibition of protein tyrosine phosphatases) 
1. Prepare 200 mM solution of sodium orthovadate [0.7356 g Na3VO4 per 20 mL] 
2. Adjust pH to 10 using NaOH or HCl (should be yellow in colour at pH 10) 
3. Boil solution until it becomes colourless (approximately 10 minutes) 
4. Cool to room temperature 
5. Re-adjust pH to 10 (until the solution remains colourless and pH stabilizes at 10) 
6. Store activated sodium orthovanadate as aliquots at -20oC   
** 0.5 M EGTA stock 
0.146 g EGTA per 1 mL R/O water  
*** 0.5 M EDTA stock  
0.190 g EDTA per 1 mL R/O water  
**** 100 mM Phenylmethylsulphonyl fluoride stock  
0.087 g phenylmethylsulfonyl fluoride in 5 mL isopropanol  
 
Appendix  E: Micro BCATM Protein Assay Kit Working Reagent  
• 25 parts Reagent A : 24 parts Reagent B : 1 part Reagent C 
For 15 mL – 7.5 mL Reagent A : 7.2 mL Reagent B : 0.3 mL Reagent C 
Appendix  F: Loading Buffer (4X) 
1. Prepare Resolving Gel  
Component 10% Gel (mL) 8% Gel (mL) 
R/O water 15.9 9.3 
30% acrylamide  13.3 5.3 
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Tris-Cl (1.5M, pH 8.8) 10.0 5.0 
10% SDS 0.4 0.2 
10% APS 0.4 0.2 
TEMED  0.016 0.012 
 
 
 
 
 
NOTE: add APS and TEMED last  
• Mix all components thoroughly and pour gel, leaving sufficient space for stacking 
gel and combs 
• Pipette water gently over gel solution to ensure no bubbles are present and gel 
polymerizes in a straight horizontal line under stacking gel 
• Allow sufficient time to polymerize (approximately 20 minutes or until a clear 
line is present between gel and overlaying water)  
• Pour off water, before preparing stacking gel  
2. Prepare Stacking Gel  
 
Component 5% Gel (mL) 
R/O water  8.2 
30% acrylamide 2.0 
Tris-Cl (1M, pH 6.8) 1.5 
10% SDS 0.12 
10% APS 0.12 
TEMED 0.012 
NOTE: Add APS and TEMED last  
• Mix all components thoroughly and pour gel, filling glass caste  
• Insert 1.5 mm combs immediately and allow gel to polymerize  
• Store in 4oC fridge wrapped in damp paper towel if not using immediately  
Appendix  G: 30% Acrylamide (100 mL) 
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• 29 g Acrylamide 
• 1 g N,N’ methylene bisacrylamide (dissolved in 60 mL distilled water) 
• Bring volume to 100mL with distilled water  
Appendix  H: 1M TRIS (pH 6.8) (500 mL) 
• 60.57 g TRIS 
• 400 mL distilled water  
• Bring volume to 500 mL once dissolved  
• Adjust pH to 6.8 using either hydrochloric acid or sodium hydroxide  
 
 
 
Appendix  I: 1.5 TRIS (pH 8.8) 
• 90 g TRIS  
• 400 mL distilled water 
• Bring volume to 500 mL once dissolved  
• Adjust pH to 6.8 using either hydrochloric acid or sodium hydroxide  
Appendix  J: Running Buffer (10X) (2 Litres) 
• 1500 mL distilled water  
• 60 g TRIS 
• 288 g Glycine 
• Bring volume up to 2000 mL 
• 20 g SDS (add last) 
Appendix  K: Transfer Buffer (5 Litres) 
• 3500 mL distilled water  
• 1000 mL methanol  
• 39 mM Glycine (14.5 g) 
• 38 mM TRIS (29 g) 
• Top up volume to 5000 mL 
• 0.0317% SDS (1.85 g) – add last  
Appendix  L: Blocking Solution (100 mL)  
• 5% non-fat milk (5 g) 
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• 100 mL PBS-T 
Appendix  M: 1X PBS-T (1 Litre) 
• Dilute 10X PBS to 1X (100 mL PBS (10X) + 900 mL distilled water) 
• 2 mL 10% TWEEN solution  
Appendix  N: Protocol for mild stripping PVDF membranes Buffer, 1 liter  
• 15 g glycine 
• 1 g SDS 
• 10 ml Tween20 
• Adjust pH to 2.2 
• Bring volume up to 1 L with R/O water.  
Membrane incubation  
1. Use a volume that will cover the membrane.  
2. Incubate at room temperature for 5-10 minutes. 
3. Discard buffer. 5-10 minutes fresh stripping buffer. 
4. Discard buffer. 10 minutes PBS twice, then 5 minutes TBST twice 
5. Ready for blocking stage. 
6. Block membrane twice for 5 minutes with 5% non-fat milk blocking solution 
7. Apply primary antibody 
 
Appendix  O: G418 (Geneticin) 
• 50 mg/mL stock dissolved in water 
• Dilute to 0.1 mg/mL when needed (ex. 20 µL in one 10 mL culture flask) 
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Appendix  P: Protein Estimation Protocol 
The BSA stock was first diluted from 2.0 mg/mL to 200 µg/mL using R/O water. 
The stock was further diluted via serial dilution to construct a standard curve from 200 
µg/mL to 1.5625 µg/mL BSA. Each unknown sample was diluted 10X with R/O water 
for a total volume of 150 µL in each well (15 µL sample + 135 µL R/O water). Once all 
standards and samples were added to the plate in duplicate, BCA reagents were mixed 
(25 parts reagent A : 24 parts reagent B : 1 part reagent), 150 µL of BCA reagent was 
added to each well and the 96-well plate was incubated for one hour at 37 oC. Absorbance 
was measured at 562 nm on the SpectraMax 190 Absorbance Microplate Reader 
(Molecular Devices) using SoftMax® Pro software. 
 
 
 
Appendix  Q: RNA Protocol 
Total RNA was isolated from 5×105 PBMC with Omega Bio-tek’s E.Z.N.A.® Total 
RNA Kit I with an elution volume of 40 µL. RNA concentrations were quantified with 
SpectraMaxR i3 spectrophotometer. 
 
Appendix  R: cDNA Synthesis kit 
Components 1X Volume 10X Volume 
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5X iScript Rxn Supermix 4 µl 40 µl 
iScript RT 1 µl 10 µl 
RNA template variable variable 
RNase free H2O variable variable 
Total volume 20 µl 200 µl 
 
Appendix  S: cDNA Thermocycler: Incubation Time 
 Time (mins) Temperature (°C) 
1 5 mins 25 °C 
2 60 mins 42 °C 
3 5 mins 85 °C 
4 Hold 4 °C 
 
 
 
Appendix  T: RT-PCR Primer Information 
Bio Rad Product 
PrimerPCR SYBR Green Assay 
Assay 
Design: 
Chromosome 
Location:  
Mapping: 
Amplicon 
Length 
(bp): 
Context Sequence 
1. Gene Symbol: NMT1 
Gene Name:     
N-myristoyltransferase 1 
RefSeq:  
Intron-
spanning 
Location: 
17:43159068-
43163945 
 
93 AGAAGAAAGAAAA
AGGCAGTGAGACA
GATTCAGCCCAGGA
TCAGCCTGTGAAGA
 58 
NC_000017.10, NT_010783.15 
Ensembl: ENSG00000136448 
Mapping 
17q21.31 
TGAACTCTTTGCCA
GCAGAGAGGATCC
AGGAAATACAGAA
GGCCATTGAGCTGT
TCTCAGTGGGTCAG
G 
2. Gene Symbol: METAP2 
Gene Name: 
Methionyl aminopeptidase 2 
RefSeq:   
NC_000012.11, NT_029419.12 
Ensembl: ENSG00000111142 
Intron-
spanning 
Location: 
12:95879687-
95887920 
 
Mapping 
12q22 
130 ATATGTGACCTGTA
TCCTAATGGTGTAT
TTCCCAAAGGACAA
GAATGCGAATACCC
ACCCACACAAGAT
GGGCGAACAGCTG
CTTGGAGAACTACA
AGTGAAGAAAAGA
AAGCATTAGATCAG
GCAAGTGAAGAGA
TTTGGAATGATTTT
CGAGAAGCTG 
3. Gene Symbol: GAPDH 
Gene Name:   
Glyceraldehyde-3-phosphate 
dehydrogenase 
RefSeq: 
NC_000012.11 NG_007073.2 
NT_009759.16 
Ensembl: ENSG00000111640 
Exonic Location: 
12:6647267-
6647413 
 
Mapping: 
12p13 
 
117 GTATGACAACGAAT
TTGGCTACAGCAAC
AGGGTGGTGGACCT
CATGGCCCACATGG
CCTCCAAGGAGTAA
GACCCCTGGACCAC
CAGCCCCAGCAAG
AGCACAAGAGGAA
GAGAGAGACCCTC
ACTGCTGGGGAGTC
 59 
CCTGCCACAC 
4.Gene Symbol: ACTB 
Gene Name: actin, beta 
RefSeq: 
NC_000007.13 NG_007992.1 
NT_007819.17 
Ensembl: ENSG00000075624 
Exonic Location: 
17:43159068-
43163945 
 
Mapping: 
7p22 
62 GTGCTCGATGGGGT
ACTTCAGGGTGAGG
ATGCCTCTCTTGCT
CTGGGCCTCGTC 
GCCCACATAGGAAT
CCTTCTGACCCATG
CCCACCATCA 
5. Gene Symbol: RPLP0 
Gene Name: 
Ribosomal protein, large, P0 
RefSeq: 
NC_000012.11 
NT_009775.17 
Ensembl: ENSG00000089157 
Exonic Location: 
12:120637113-
120637205 
 
Mapping: 
12q24.2 
63 TTCTCCAGAGCTGG
GTTGTTTTCCAGGT
GCCCTCGGATGGCC
TTGCGCATCATGGT
GTTCTTGCCCATCA
GCACCACAGCCTTC
CCGCGAAGG 
 
 
 
Appendix  U: RT-PCR SYBR Green Mastermix 
BIORAD REAGENTS 1X Volume 10X Volume 
SsoAdvanced Universal supermix 7.5 µl 75 µl 
Primer  0.75 µl 7.5 µl 
cDNA (10ng/ µl) X 2 µl = 20ng 2 µl 20 µl 
RNase free H2O 4.75 µl 47.5 µl 
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Appendix  V: Whole Blood Study: Patient’s Colonoscopy/ Pathology Report 
Patient Sample Gender/Age Polyps Diagnosis CRC 
1 Control 1 F/ 38 No Normal No 
2 Control 2 F/ 70 No Normal No 
3 Control 3 M/ 31 No Normal No 
4 NAP 1 M/ 60 Yes (4) Single diminutive sessile polyp (2) No 
5 NAP 2 M/ 38 Yes (2) 1. Single sessile polyp 
2. Pseudopolyp 
No 
6 NAP 3 F/ 64 Yes (1) Hyperplastic polyp (1) No 
7 NAP 4 F/ 65 Yes (6) Single sessile polyp (6) No 
8 AP 1 M/ 77 Yes (6) Tubular Adenoma (6) No 
9 AP 2 F/ 71 Yes (1) Tubular Adenoma (1) No 
10 AP 3 F/ 49 Yes (3) 1. Tubular Adenoma (1) 
2. Single sessile polyp (1) 
3. Hyperplastic polyp (1) 
No 
11 AP 4 F/ 67 Yes (4) 1. Tubular Adenoma (1) 
2. Single sessile polyp (3) 
No 
12 CRC 1 F/ 69 Yes (2) Adenocarcinoma Yes 
13 CRC 2 F/ 52 Yes (3) Adenocarcinoma Yes 
14 CRC 3 F/ 51 Yes (2) Adenocarcinoma Yes 
15 CRC 4 M/ 73 Yes (3) Adenocarcinoma Yes 
16 CRC 5 F/ 75 Yes (2) Adenocarcinoma Yes 
17 CRC 6 F/ 69 Yes (1) Adenocarcinoma Yes 
18 CRC 7 M/ 44 Yes (1) Adenocarcinoma Yes 
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Appendix  W: PBMC Study: Patients’ Colonoscopy/ Pathology Report 
Patient Sample Gender/Age Polyps Diagnosis CRC 
1 Control 1 F/ 44 No Normal No 
2 Control 2 F/ 54 No Normal No 
3 Control 3 M/ 73 No Normal No 
4 Control 4 F/ 53 No Normal No 
5 Control 5 F/ 61 No Normal No 
6 Control 6 M/ 27 No Normal No 
7 Control 7 F/ 52 No Normal No 
8 Control 8 M/ 66 No Normal No 
9 Control M/51 No Normal No 
10 NAP 1 M/ 58 Yes (2) 1. Pseudopolyp 
2. Hyperplastic polyp 
No 
11 NAP 2 M/ 73 Yes (1) Single sessile polyp No 
12 NAP 3 M/ 38 Yes (2) 1. Single sessile polyp 
2. Pseudopolyp 
No 
13 NAP 4 F/ 65 Yes (6) Single sessile polyp (6) No 
14 NAP 5 M/ 53 Yes (1) Single sessile polyp No 
15 NAP 6 M/ 67 Yes (1) Pseudopolyp No 
16 NAP 7 F/ 67 Yes (1) Single sessile polyp No 
17 AP 1 M/ 55 Yes (4) 1. Tubular Adenoma (1) 
2. Hyperplastic polyp (3) 
No 
18 AP 2 F/ 72 Yes (8) 1. Tubular Adenoma (3) 
2. Hyperplastic polyp (2) 
No 
 62 
3. Single diminutive sessile polyp 
(1) 
4. Diminutive sessile polyp (1) 
5. Flat polyp (1) 
19 AP 3 M/ 38 Yes (4) 1. Tubular Adenoma (1) 
2. Single diminutive sessile polyp 
(1) 
3. Diminutive sessile polyp (2) 
No 
20 AP 4 M/ 83 Yes (9) 1. Tubular Adenoma (1) 
2. Hyperplastic polyp (5) 
3. Single diminutive sessile polyp 
(2) 
4. Diminutive sessile polyp (1) 
No 
21 AP 5 M/ 67 Yes (1) Tubular Adenoma (1) No 
22 AP 6 F/ 65 Yes (3) 1. Tubular Adenoma (1) 
2. Single diminutive sessile polyp 
(1) 
3. Diminutive sessile polyp (1) 
No 
23 CRC 1 M/ 73  Yes (3) Adenocarcinoma Yes 
24 CRC 2 F/ 69 Yes (1) Adenocarcinoma Yes 
25 CRC 3 F/ 71 Yes (1) Adenocarcinoma Yes 
 
 
